On September 25, the selection results for the "2024 Top 20 Most Competitive Listed Pharmaceutical Companies in China" were announced. Organized by the China Pharmaceutical Enterprise Association, this prestigious industry event has been held for 16 consecutive years since 2009. JumpCan Pharmaceutical, an A-share listed company, has once again been included on the list, demonstrating its strong sustainable competitiveness, potential, and value in the pharmaceutical market.
JumpCan Pharmaceutical has consistently adhered to its "Four-One" value philosophy: "To sustain steady growth for the enterprise, to ensure rising income for our employees, to make meaningful tax contributions to the government, and to fulfill our responsibilities with dedication to both society and shareholders." Following the principles of true, accurate, complete, timely, and fair information disclosure, the company has received an A-grade rating for information disclosure from the Shanghai Stock Exchange for three consecutive years. In 2023, the company achieved an operating revenue of RMB 9.655 billion, with a net profit attributable to the parent company of RMB 2.823 billion and a non-GAAP net profit of RMB 2.692 billion.
JumpCan Pharmaceutical remains committed to innovation-driven development and actively embraces transformation. The company is accelerating the R&D of innovative and improved drugs, advancing the construction of a modern pharmaceutical industry, continuously developing new quality productive forces, and strengthening its presence in key therapeutic areas. Over the past three years, its R&D investment has exceeded RMB 1.5 billion. JumpCan Pharmaceutical has consistently achieved drug R&D outcomes with high technological barriers and significant clinical value. Since 2022, the company has obtained approvals for 16 new products, among which Xiao'er Chiqiao Qingre Syrup (K-tonpei) is the first improved traditional Chinese medicine (TCM) drug launched since the implementation of the new Drug Registration Management Measures. This year, JumpCan Pharmaceutical also has gained approval for China's first Fexofenadine Hydrochloride for Suspension and has been honored with the National Science and Technology Progress Award twice within five years, demonstrating continuous breakthroughs and strong innovation potential on its R&D journey.
Focusing on its medium-to-long-term development strategy and market demands, the company facilitates expansive growth through business development. It has established an R&D system that integrates independent innovation and collaborative research, introducing innovative drugs such as innovative fusion protein-based long-acting growth hormone, oral PDE4 (phosphodiesterase 4) inhibitor, drug-targeted digestive protease inhibitor, and polymerase acidic protein (PA) endonuclease inhibitors for the treatment or prevention of influenza. The steady progress of BD projects has injected new momentum into JumpCan Pharmaceutical’s medium-to-long-term development.
This year, the company released its 2024 "Quality, Efficiency, and Returns Enhancement" action plan, outlining a clear commitment to building future-oriented core competitiveness. Efforts will focus on product cooperation and introduction, active development in improved innovation R&D fields and technology platforms, and rapid advancement of a lean manufacturing model excelling in "safety, standardization, quality, and cost." The company will also vigorously enhance talent acquisition and collaborative management capabilities, strategically position itself for medium-to-long-term growth opportunities, and achieve high-quality development goals.